Table 1.
Epidemiological characteristic of PD patients
| pRBD+ | pRBD- | p | |
|---|---|---|---|
| Patients number (n) | 30 | 111 | |
| Age (yr) | 68.33 ± 8.76 | 69.32 ± 9.75 | 0.618 |
| PD duration (yr) | 4.13 ± 4.22 | 4.65 ± 3.57 | 0.500 |
| Gender, male, n (%) | 18 (60.00) | 56 (50.45) | 0.655 |
| Smoking, n (%) | 4 (13.3) | 11 (9.91) | 0.525 |
| Alcohol, n (%) | 0 | 9 (8.11) | 0.204 |
| Coffee, n (%) | 1 (3.33) | 5 (4.50) | 1.0 |
| Levodopa dose equivalent (mg/day) | 353.53 ± 236.10 | 339.10 ± 272.08 | 0.531 |
| Levodopa dose (mg/day) | 325.00 ± 205.84 | 285.15 ± 250.09 | 0.221 |
| Levodopa years | 2.59 ± 3.08 | 3.03 ± 3.31 | 0.577 |
| Dopa agonist dose (mg/day) | 38.23 ± 51.01 | 33.19 ± 45.12 | 0.931 |
| Dopa agonist years | 0.91 ± 1.52 | 4.41 ± 29.21 | 0.479 |
| TCA(Deanxit), n (%) | 1 (0.033) | 1 (0.009) | >0.90 |
| Trihexyphenidyl, n (%) | 4 (0.133) | 18 (0.162) | >0.90 |
| SSRI, n (%) | 2 (0.067) | 3 (0.027) | >0.75 |
| BNZ, n (%) | 6 (0.2) | 3 (0.027) | <0.005 |
SSRI Selective Serotonin Reuptake Inhibitor
BNZ Benzodiazepines, n: number
The age, mean PD duration years, smoking, alcohol and coffee consumption rates, levodopa had no difference between two groups. However, the pRBD+ group had greater antidepressant and antihypnotic use